Mostafa Javanian1, Masomeh Bayani1, Mehran Shokri1, Mahmoud Sadeghi-Haddad-Zavareh1, Arefeh Babazadeh1, Babak Yeganeh1, Sima Mohseni1, Rahele Mehraeen2, Mahdi Sepidarkish3, Ali Bijani4, Ali Rostami1, Mehdi Shahbazi5, Afrooz Monadi Tabari1, Asieh Shabani6, Jila Masrour-Roudsari1, Amir Hossein Hasanpour7, Hossein Emam Gholinejad7, Hossein Ghorbani8, Soheil Ebrahimpour1. 1. Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, I.R. Iran. 2. Department of Radiology, Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran. 3. Department of Biostatistics and Epidemiology, Babol University of Medical Sciences, Babol, Iran. 4. Social Departments of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, I.R. Iran. 5. Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran. 6. Clinical Research Development Unite of Rouhani Hospital, Babol University of Medical Sciences, Babol, I.R. Iran. 7. Student Research Committee, Babol University of Medical Sciences, Babol, Iran. 8. Department of Pathology, Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran.
Abstract
BACKGROUND: In December 2019, China has experienced an outbreak of novel coronavirus disease 2019 (COVID-19). Coronavirus has now spread to all of the continents. We aimed to consider clinical characteristics, laboratory data of COVID-19 that provided more information for the research of this novel virus. METHODS: We performed a retrospective cohort study on the clinical symptoms and laboratory findings of a series of the 100 confirmed patients with COVID-19. These patients were admitted to the hospitals affiliated to Babol University of Medical Sciences (Ayatollah Rohani, Shahid Beheshti and Yahyanejad hospitals) form 25 February 2020 to 12 March 2020. RESULTS: Nineteen patients died during hospitalization and 81 were discharged. Non-survivor patients had a significantly higher C-reactive protein (CRP) (MD: 46.37, 95% CI: 20.84, 71.90; P = 0.001), white blood cells (WBCs) (MD: 3.10, 95% CI: 1.53, 4.67; P < 0.001) and lower lymphocyte (MD: -8.75, 95% CI: -12.62, -4.87; P < 0.001) compared to survivor patients Data analysis showed that comorbid conditions (aRR: 2.99, 95% CI: 1.09, 8.21, P = 0.034), higher CRP levels (aRR: 1.02, 95% CI: 1.01, 1.03, P = 0.044), and lower lymphocyte (aRR: 0.82, 95% CI: 0.73, 0.93, P = 0.003) were associated with increased risk of death. CONCLUSIONS: Based on our findings, most non-survivors are elderly with comorbidities. Lymphopenia and increased levels of WBCs along with elevated CRP were associated with increased risk of death. Therefore, it is best to be regularly assessed these markers during treatment of COVID-19 patients.
BACKGROUND: In December 2019, China has experienced an outbreak of novel coronavirus disease 2019 (COVID-19). Coronavirus has now spread to all of the continents. We aimed to consider clinical characteristics, laboratory data of COVID-19 that provided more information for the research of this novel virus. METHODS: We performed a retrospective cohort study on the clinical symptoms and laboratory findings of a series of the 100 confirmed patients with COVID-19. These patients were admitted to the hospitals affiliated to Babol University of Medical Sciences (Ayatollah Rohani, Shahid Beheshti and Yahyanejad hospitals) form 25 February 2020 to 12 March 2020. RESULTS: Nineteen patientsdied during hospitalization and 81 were discharged. Non-survivor patients had a significantly higher C-reactive protein (CRP) (MD: 46.37, 95% CI: 20.84, 71.90; P = 0.001), white blood cells (WBCs) (MD: 3.10, 95% CI: 1.53, 4.67; P < 0.001) and lower lymphocyte (MD: -8.75, 95% CI: -12.62, -4.87; P < 0.001) compared to survivor patients Data analysis showed that comorbid conditions (aRR: 2.99, 95% CI: 1.09, 8.21, P = 0.034), higher CRP levels (aRR: 1.02, 95% CI: 1.01, 1.03, P = 0.044), and lower lymphocyte (aRR: 0.82, 95% CI: 0.73, 0.93, P = 0.003) were associated with increased risk of death. CONCLUSIONS: Based on our findings, most non-survivors are elderly with comorbidities. Lymphopenia and increased levels of WBCs along with elevated CRP were associated with increased risk of death. Therefore, it is best to be regularly assessed these markers during treatment of COVID-19patients.
Authors: Felix M Reyes; Manuel Hache-Marliere; Dimitris Karamanis; Cesar G Berto; Rodolfo Estrada; Matthew Langston; George Ntaios; Perminder Gulani; Chirag D Shah; Leonidas Palaiodimos Journal: J Clin Med Date: 2021-05-13 Impact factor: 4.241
Authors: Stephan Katzenschlager; Alexandra J Zimmer; Claudius Gottschalk; Jürgen Grafeneder; Stephani Schmitz; Sara Kraker; Marlene Ganslmeier; Amelie Muth; Alexander Seitel; Lena Maier-Hein; Andrea Benedetti; Jan Larmann; Markus A Weigand; Sean McGrath; Claudia M Denkinger Journal: PLoS One Date: 2021-07-29 Impact factor: 3.240
Authors: Chirag Bavishi; Robert O Bonow; Vrinda Trivedi; J Dawn Abbott; Franz H Messerli; Deepak L Bhatt Journal: Prog Cardiovasc Dis Date: 2020-06-06 Impact factor: 8.194